ClinicalTrials.gg
CompletedNCT06380881Updated Nov 18, 2025

PK/PD Study of SHR-2017 Injection in Patients With Bone Metastases

A Phase 1 interventional study of SHR-2017 in Patients With Bone Metastases, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-18.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 485 studies in Neoplasm Metastasis with a site in China — 222 open to participants now, 263 under way, 40 of them phase 3. Neoplasm Metastasis · China.

Enrollment
341st of 401
25 · median 90
Started
2024
with 44 others
Phase 1
93 of 485
47 open now
Registered
319th of 485
by date

Among the 485 studies in Neoplasm Metastasis with a site in China, this one is the 341st largest by enrollment of the 401 interventional ones that give a count, is one of 45 that started in 2024, is one of 93 in phase 1, and was the 319th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

222 of the 485 studies in Neoplasm Metastasis with a site in China are open now. Recruiting first, the newest first:

217 more — sign in →

All 222 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 485 studies in Neoplasm Metastasis with a site in China, or all of them as a file.
02

Study summary

To evaluate the pharmacokinetic characteristics, pharmacodynamic characteristics, safety, tolerability and immunogenicity of SHR-2017 injection in patients with bone metastases, and to evaluate the efficacy of SHR-2017 injection in the treatment of skeletal-related event and cancer pain.

03

Conditions studied

  • Patients With Bone Metastases

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide a written
  2. Male or female, age ≥ 18 years;
  3. Solid tumors confirmed by histological or cytological examination;
  4. At least 1 bone from a documented tertiary A hospital during the screening period;
  5. Worst pain score NRS ≥5 points when treated with a stable analgesic regimen during the baseline assessment period;
  6. Received a stable anti-tumor regimen within 28 days prior to the baseline assessment period
  7. During the screening period, the physical status score of the (ECOG) was 0-2 points;
  8. judged by the investigator to be at least 6 months
  9. Good organ function during the screening period (repeated testing can be confirmed if necessary);
  10. Female subjects of with negative blood pregnancy test results within 7 days prior to the first dose of study drug and not lactating.

Exclusion criteria

Exclusion Criteria:

  1. Previous occurrence or concomitant osteomyelitis of the jaw or osteonecrosis of the jaw, dental disease or jaw disease that is active, requiring oral surgery, dental surgery or oral surgery wound that has not fully healed, or has planned invasive dental procedures during the study;
  2. History of major joint trauma or surgery within 1 year prior to enrollment
  3. Cardiac dysfunction Within 6 months before enrollment;
  4. Resting tachycardia or resting bradycardia on at screening;
  5. Subjects who have evidence of orthostatic hypotension at screening;
  6. surface antigen (HBSAG), antibody (HCVAB), human immune defect antivirus () antibody, syphilis antibody;
  7. The pain of the subjects not predominantly related to a bone ;
  8. The subject with neurological diseases and/or mental illness and/or cognitive dysfunction ;
  9. Receipt of radiopharmaceutical treatment or radiotherapy for treatment of bone metastasis within 1 month of the treatment period, and the subject who received the radiotherapy within one month before the first research drug administration
  10. Subject has a history of allergic or anaphylactic reaction to mammalian -based drugs, or allergies to supplements (calcium or vitamin D supplements), or have a history of allergens of opioids, or past history of treatment or diagnostic monoclonal antibody, Or other allergies;
  11. The subject participated in the treatment of other clinical trials within one month before receiving the experimental drug (except for participating in other clinical trial screening losers);
  12. In the judgment of the investigator, would make the subject inappropriate for entry into this study;
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    SHR-2017

    Drug: SHR-2017

Interventions

  • DrugSHR-2017

    SHR-2017

06

What researchers measure

Primary outcomes

  1. The Pharmacokinetic parameters of SHR-2017 after administration, including Cmax

    Time frame: First dose up to 169 days post-dose

  2. The Pharmacokinetic parameters of SHR-2017 after administration, including Tmax

    Time frame: First dose up to 169 days post-dose

  3. The Pharmacokinetic parameters of SHR-2017 after administration, including AUC0-t

    Time frame: First dose up to 169 days post-dose

  4. The Pharmacokinetic parameters of SHR-2017 after administration, including AUC0-∞

    Time frame: First dose up to 169 days post-dose

  5. The Pharmacokinetic parameters of SHR-2017 after administration, including t1/2

    Time frame: First dose up to 169 days post-dose

  6. The Pharmacokinetic parameters of SHR-2017 after administration, including CL/F

    Time frame: First dose up to 169 days post-dose

  7. The pharmacodynamic parameter of SHR-2017 after administration include uNTX/uCr

    Time frame: First dose up to 169 days post-dose

  8. The pharmacodynamic parameter of SHR-2017 after administration include β-CTX

    Time frame: First dose up to 169 days post-dose

  9. The pharmacodynamic parameter of SHR-2017 after administration include BALP [Time

    Time frame: First dose up to 169 days post-dose

Secondary outcomes

  1. Change from baseline in worst pain/average pain at the designated bone metastasis pain site after dosing

    Worst pain / average pain was assessed on an 11-point numeric rating scale (NRS) ,The participant described the worst pain/average pain during the past 24 hours on a scale ranging from 0 (no pain) to 10 (worst possible pain)

    Time frame: First dose up to 169 days post-dose

  2. Incidence of skeletal-related event

    Time frame: First dose up to 169 days post-dose

  3. Average daily total opioids consumption

    Time frame: First dose up to 169 days post-dose]

07

Study locations

1 site
  • Beijing Cancer Hospital
    Beijing, Beijing Municipality 100142, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Aug 2025, 14 months.

Of 287 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's 14 months is below that.

Counting every sponsor, half of 497 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2024
First posted
Apr 24, 2024
StartActual
May 20, 2024
Primary completionActual
Aug 6, 2025
CompletionActual
Aug 6, 2025
Last update
Nov 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06380881
Responsible party
Sponsor
First posted
Apr 24, 2024
Start date
May 20, 2024
Primary completion
Aug 6, 2025
Completion
Aug 6, 2025
Last update
Nov 18, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion